News on China's scientific and technological development.


zgx09t

Junior Member
Registered Member
The political persecution of China born scientist in the land of the free. There was a whole series of them, trotting out painful nerve wracking stories to scare the Chinese science community in America.

That poor guy suffered a lot.

 

taxiya

Colonel
Registered Member
The political persecution of China born scientist in the land of the free. There was a whole series of them, trotting out painful nerve wracking stories to scare the Chinese science community in America.

That poor guy suffered a lot.

Scapegoat hunting in U.S. is nothing new, nor will it disappear soon. Americans of German decent during the WWI, Japanese Americans during WWII were all subjected to persecution for their place of birth, all because of their ancestral countries were at odd with U.S. Now it is the turn of Chinese Americans as China is restoring its strength.

Just saying it is no surprising. One lesson for everybody is that be careful switching your life boat when the sea is rough.
 

zgx09t

Junior Member
Registered Member
Scapegoat hunting in U.S. is nothing new, nor will it disappear soon. Americans of German decent during the WWI, Japanese Americans during WWII were all subjected to persecution for their place of birth, all because of their ancestral countries were at odd with U.S. Now it is the turn of Chinese Americans as China is restoring its strength.

Just saying it is no surprising. One lesson for everybody is that be careful switching your life boat when the sea is rough.

"Nothing new"," no surprising" carry an unfortunate connotation of belittling the genuine suffering of the guy in this case.
"Nothing new"," no surprising" do not describe, justify or make it any less painful of what happened to the guy.
Rape and murder are nothing new, nor surprising, until that actually happens to someone just a few degrees of separation too close to your comfort, then you would understand the full import of the words injustice and injury to human dignity. Frequency alone doesn't justify the actions.
"Nothing new"," no surprising" is pretty much like spitting in that poor guy face and telling him get over with it already.
I don't really think that would be acceptable to you, or anybody else.
 

taxiya

Colonel
Registered Member
"Nothing new"," no surprising" carry an unfortunate connotation of belittling the genuine suffering of the guy in this case.
"Nothing new"," no surprising" do not describe, justify or make it any less painful of what happened to the guy.
Rape and murder are nothing new, nor surprising, until that actually happens to someone just a few degrees of separation too close to your comfort, then you would understand the full import of the words injustice and injury to human dignity. Frequency alone doesn't justify the actions.
"Nothing new"," no surprising" is pretty much like spitting in that poor guy face and telling him get over with it already.
I don't really think that would be acceptable to you, or anybody else.
First of all, this is way off topic of this thread "China's scientific and technological development".
On the topic of "human dignity". None of these that you have presented are acceptable to anyone, me included. You got that right.
But, back to reality, do you preach "human dignity" everywhere, anytime, day and night, and most importantly fighting for it JUST like the western powers do (everywhere, all the time) in the name of "human right"? You maybe do. But I don't, not here when the subject is "China, Science and Technology".
I share with your sentiment, but I disagree with your getting excited about it everywhere.
 

supercat

Junior Member
FDA Approves First Chinese Cancer Drug for U.S. Patient Use
Bloomberg News
November 14, 2019, 11:27 PM EST Updated on November 15, 2019, 4:27 AM EST
  • Beijing-based BeiGene’s Brukinsa treats blood cancer
  • New drug will compete with therapies from AbbVie, AstraZeneca
The
Please, Log in or Register to view URLs content!
has granted approval to a blood cancer drug from Beijing-based
Please, Log in or Register to view URLs content!
, paving the way for American patients to access a Chinese cancer therapy for the first time.

The accelerated approval -- ahead of even China’s own national drug regulator -- marks a breakthrough for the growing legion of Chinese biotech companies determined to take on the world’s biggest pharmaceutical companies in medical innovation and scientific research.

“This means we are not only bringing new drugs into China, we are also bringing new drugs from China to the whole world,“ said BeiGene President Wu Xiaobin at a press conference on Friday in Beijing. “Chinese biotech is on the rise. The industry is not yet on top of the world but we are quickly closing the gap.”

BeiGene’s Brukinsa capsules was approved for patients with mantle cell lymphoma that have already received other therapies earlier, and will be a competitor to similar blood cancer therapies from
Please, Log in or Register to view URLs content!
and
Please, Log in or Register to view URLs content!
. BeiGene’s Hong Kong-listed shares rose 6.6% to a record high on Friday.

Please, Log in or Register to view URLs content!


Investment into Chinese biotech startups is surging as the opening up of the Asian giant’s $132 billion pharmaceutical market creates an unprecedented profit-making opportunity for health-care companies. Last week, AstraZeneca announced a $1 billion
Please, Log in or Register to view URLs content!
with a Chinese investment bank to support local drug research, while a Shanghai-based company received Chinese regulatory approval for the first new Alzheimer’s
Please, Log in or Register to view URLs content!
in 17 years.

BeiGene has emerged as one of the most promising Chinese biotech companies and the new drug, also known as zanubrutinib, is the first in a raft of cancer drugs it is readying for regulatory approval. In a vote of confidence in its pipeline, American generics giant
Please, Log in or Register to view URLs content!
bought a 20.5% stake in BeiGene earlier this month for $2.7 billion to jointly develop cancer therapies.

BeiGene said it expects to see another one of its cancer drugs, Tislelizumab, approved by the Chinese regulator by the end of this year. It has not yet disclosed pricing details for Brukinsa.

Please, Log in or Register to view URLs content!
 

nugroho

Junior Member
Beigene is chinese company , but more than 50% of it's shares are held by foreign investor. Chinese investment institutions and brokerages should ramp up their share in this kind of company, because in the future this kind will be the " battlefield " of biopharmaceutical tech war
 

localizer

Colonel
Registered Member
Please, Log in or Register to view URLs content!


Megacore launches 100% code ownership rate fifth generation series CPU
From: Big Semiconductor Industry Network

The new product launch conference of the KX-5000 series processor was held in Shanghai on December 28th. With the release of two 4/8 core KX-5000 and one 8-core KH-20000 series processor, On the occasion of the 5th anniversary of its upcoming glory, Zhaoxin successfully launched the 5th generation general-purpose CPU products.

The KX-5000 series processors from Zhaoxin for PC, embedded industrial control and thin client are divided into 4 cores and 8 cores. The design is optimized for the main frequency, core, power consumption and system for different market demands. . Ye Jun, chairman and general manager of Zhaoxin, said that this is the first general-purpose CPU designed by SoC with SoC design, and it is also the first domestic general-purpose CPU supporting dual-channel DDR4 memory, which is the main domestic desktop general-purpose processor market. The KX-5000 next-generation processor is aimed at the consumer market.

The KX-5000 uses a 28nm process to achieve a 2.2G main frequency, which is the embodiment of the powerful design and development strength of Megacore. According to reports, in every link, Zhaoxin is implemented with the industry's highest standards and the most advanced specifications. At the same time, the micro-architecture independently developed by Zhaoxin, the ability to design IP independently, the self-developed simulation and simulation test environment, etc. This kind of autonomous, no third-party design and development process has given Zhaoyuan a great deal of coordination and optimization space. Zhaoxin believes that this is a condition that many domestic CPU design and development companies do not have.
 
Jun 17, 2019
Saturday at 5:46 PM
in fact today:
Please, Log in or Register to view URLs content!


little need to change my favorite chart
again:
China Extends Lead in Number of TOP500 Supercomputers, US Holds on to Performance Advantage
November 18, 2019 08:04 CET
Please, Log in or Register to view URLs content!
 
Jun 17, 2019
again:
China Extends Lead in Number of TOP500 Supercomputers, US Holds on to Performance Advantage
November 18, 2019 08:04 CET
Please, Log in or Register to view URLs content!
I think China has basically decided that amid the Trump hostilities, it is no longer willing to divulge the true capabilities of its top systems as that knowledge provides information with which to predict how much China's key industries and military can benefit from them. Indeed, in June, it withheld more than one Shuguang supercomputers that were said to be over 50% more powerful than America's top system. I can't find any more public information on how much they or other new Chinese designs have improved since then but China's continued ascent on the number of TOP500 systems as well as capability of their aggregate performance (even without the big guns) strongly suggests parallel improvements to its elite supercomputers.

Please, Log in or Register to view URLs content!
 

Top